Intangible Assets and Goodwill - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 26, 2023
Goodwill [Line Items]
Amortization and impairment of acquired intangible assets	$ 86,900,000	$ 52,900,000	$ 165,200,000	$ 103,100,000
Impairment of intangible assets	0	$ 0	0	$ 0
Accumulated impairment losses related to goodwill	$ 0		$ 0
Acquired and in-licensed rights and patents
Goodwill [Line Items]
Weighted-Average remaining useful life	12 years		12 years
Acquired and in-licensed rights and patents | Minimum
Goodwill [Line Items]
Estimated life (in years)	2 years		2 years
Acquired and in-licensed rights and patents | Maximum
Goodwill [Line Items]
Estimated life (in years)	22 years		22 years
Developed technology and other
Goodwill [Line Items]
Weighted-Average remaining useful life	10 years		10 years
Developed technology and other | Minimum
Goodwill [Line Items]
Estimated life (in years)	13 years		13 years
Developed technology and other | Maximum
Goodwill [Line Items]
Estimated life (in years)	31 years		31 years
Completed Technology | Minimum
Goodwill [Line Items]
Estimated life (in years)	2 years		2 years
Completed Technology | Maximum
Goodwill [Line Items]
Estimated life (in years)	31 years		31 years
Reata Pharmaceuticals, Inc | In-process research and development
Goodwill [Line Items]
Intangible assets:	$ 2,300,000,000		$ 2,300,000,000		$ 2,300,000,000
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)
Goodwill [Line Items]
Intangible assets:	4,200,000,000		4,200,000,000		4,200,000,000
Reata Pharmaceuticals, Inc | Priority review voucher
Goodwill [Line Items]
Intangible assets:	$ 100,000,000.0		$ 100,000,000.0		$ 100,000,000